The myth that testosterone replacement in men causes prostate cancer has been around for over 60 years.   In 1941, Dr. Charles B. Huggins, a urologist at the University of Chicago published a study linking testosterone and prostate cancer.  From 1941 to 1991 there was very little testosterone use in the United States because physicians were convinced they would be putting men at risk.

Dr. Abraham Morgentaler, an associate clinical professor of urology at Harvard Medical School is an expert on the topic of prostate health and testosterone.  During his career as a Urologist, he noticed that what he was taught about the prostate and testosterone and what was actually happening with his patients did not match.  He saw countless men suffering from low testosterone who were denied treatment due to the unfounded fears of their health care providers.  These  men with low testosterone were at a higher risk for heart disease, alzheimers, diabetes and osteoporosis in addition to having a lower quality of life.

When Dr. Morgentaler took a closer look at Dr. Huggins research from 1941, he realized that the conclusion that testosterone causes prostate cancer had been made using the clinical results of ONE patient.   The recent research indicates that the increased risk from exposure to testosterone occurs in testosterone levels between 0-240ng/dl.  This is why pharmaceutical or surgical castration is still used as a treatment for advanced prostate cancer.  There is no proven increased risk of prostate cancer in testosterone levels between 240ng/dl and 1000nd/dl.  Nearly all of the men being treated for low testosterone fall within this range.  The appropriately treated men get all of the benefits of optimal testosterone levels without a measurably increased risk for developing prostate cancer.

If you or someone you care about is suffering from inadequate hormone levels there may be safe and effective treatment options available from Grace G. Evins, MD.

 

 

Written by HealthspanMDs

References

Morgantaler A. Testosterone replacement therapy and prostate cancer. Urol Clin N Am. 2007;52:623-5

Rhoden EL, Morgantaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J urol.2003;170:2348-51

Shores MM, Moceri VM, Gruenwals DA, et al. low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc. 2004; 54:2077-81